{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013167","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.811380+00:00","generated_at":"2026-05-30T19:26:29.557153+00:00","sec_items":["1.01","5.03","2.01","3.02","3.03","5.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Virios acquires Pharmagesic, receives $19.5M loan, appoints new board, changes name to Dogwood Therapeutics","bullets":["Acquired 100% of Pharmagesic from Sealbond; issued 211,383 common shares and ~2,108 Series A convertible preferred shares.","Received $19.5M loan from CKLS affiliate; $16.5M funded at close, $3M due Feb 2025.","Existing shareholders get CVR entitling to 87.75% of future Halneuron milestone payments over 7 years.","Board: Richard Burch resigned; Alan Yu and Melvin Toh (CKLS) appointed; Angela Walsh promoted to CFO.","Name change to Dogwood Therapeutics; stockholder meeting required for conversion and reverse split."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013167","json":"https://secwatch.observer/filing/0001558370-24-013167.json","markdown":"https://secwatch.observer/filing/0001558370-24-013167.md","text":"https://secwatch.observer/filing/0001558370-24-013167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/viri-20241004x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:26:29.557153+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ad820aa36","claim":"Angela Walsh changed role as Chief Financial Officer at Dogwood Therapeutics, Inc..","evidence_excerpt":"promoted Angela Walsh from her prior role of Senior Vice President of Finance to the Company’s Chief Financial Officer, effective immediately upon the Closing on October 7, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"84ee4cb9e5","claim":"Richard Burch resigned as Director at Dogwood Therapeutics, Inc..","evidence_excerpt":"accepted the resignation of Richard Burch from the Board, effective as of immediately prior to the Closing on October 7, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"9e7fedaf2b","claim":"Melvin Toh was appointed as Director at Dogwood Therapeutics, Inc..","evidence_excerpt":"and Melvin Toh as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e95e10bf54","claim":"Alan Yu was appointed as Director at Dogwood Therapeutics, Inc..","evidence_excerpt":"appointed Alan Yu as a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024013167/0001558370-24-013167-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}